Home > Publications database > Cardiovascular risk factors, living and ageing in Halle: the CARLA study. > print

001     178372
005     20240229143544.0
024 7 _ |a 10.1007/s10654-021-00824-7
|2 doi
024 7 _ |a pmid:34978665
|2 pmid
024 7 _ |a 0393-2990
|2 ISSN
024 7 _ |a 1573-7284
|2 ISSN
037 _ _ |a DKFZ-2022-00022
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Hassan, Lamiaa
|b 0
245 _ _ |a Cardiovascular risk factors, living and ageing in Halle: the CARLA study.
260 _ _ |a Dordrecht [u.a.]
|c 2022
|b Springer Science + Business Media B.V.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1645446938_26267
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 37, pages 103–116 (2022)
520 _ _ |a The CARLA study (Cardiovascular Disease, Living and Ageing in Halle) is a longitudinal population-based cohort study of the general population of the city of Halle (Saale), Germany. The primary aim of the cohort was to investigate risk factors for cardiovascular diseases based on comprehensive cardiological phenotyping of study participants and was extended to study factors associated with healthy ageing. In total, 1779 probands (812 women and 967 men, aged 45-83 years) were examined at baseline (2002-2005), with a first and second follow-up performed 4 and 8 years later. The response proportion at baseline was 64.1% and the reparticipation proportion for the first and second follow-up was 86% and 77% respectively. Sixty-four percent of the study participants were in retirement while 25% were full- or partially-employed and 11% were unemployed at the time of the baseline examination. The currently running third follow-up focuses on the assessment of physical and mental health, with an intensive 4 h examination program, including measurement of cardiovascular, neurocognitive, balance and gait parameters. The data collected in the CARLA Study resulted in answering various research questions in over 80 publications, of which two thirds were pooled analyses with other similar population-based studies. Due to the extensiveness of information on risk factors, subclinical conditions and evident diseases, the biobanking concept for the biosamples, the cohort representativeness of an elderly population, and the high level of quality assurance, the CARLA cohort offers a unique platform for further research on important indicators for healthy ageing.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Cardiovascular diseases
|2 Other
650 _ 7 |a Elderly population
|2 Other
650 _ 7 |a Healthy ageing
|2 Other
650 _ 7 |a Population-based cohort study
|2 Other
700 1 _ |a Efremov, Ljupcho
|b 1
700 1 _ |a Großkopf, Anne
|b 2
700 1 _ |a Kartschmit, Nadja
|b 3
700 1 _ |a Medenwald, Daniel
|b 4
700 1 _ |a Schott, Artjom
|b 5
700 1 _ |a Schmidt-Pokrzywniak, Andrea
|b 6
700 1 _ |a Lacruz, Maria E
|b 7
700 1 _ |a Tiller, Daniel
|b 8
700 1 _ |a Kraus, Frank Bernhard
|b 9
700 1 _ |a Greiser, Karin H
|0 P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b
|b 10
|u dkfz
700 1 _ |a Haerting, Johannes
|b 11
700 1 _ |a Werdan, Karl
|b 12
700 1 _ |a Sedding, Daniel
|b 13
700 1 _ |a Simm, Andreas
|b 14
700 1 _ |a Nuding, Sebastian
|b 15
700 1 _ |a Kluttig, Alexander
|0 0000-0003-4446-9938
|b 16
700 1 _ |a Mikolajczyk, Rafael
|b 17
773 _ _ |a 10.1007/s10654-021-00824-7
|0 PERI:(DE-600)2004992-4
|p 103–116
|t European journal of epidemiology
|v 37
|y 2022
|x 0393-2990
909 C O |p VDB
|o oai:inrepo02.dkfz.de:178372
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)e0ac0d57cdb66d87f2d95ae5f6178c1b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2022
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-28
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
|d 2022-11-17
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-17
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J EPIDEMIOL : 2021
|d 2022-11-17
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b EUR J EPIDEMIOL : 2021
|d 2022-11-17
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21